Regenxbio (RGNX) Cash from Operations Growth (1y) (2015 - 2025)
Regenxbio (RGNX) Cash from Operations Growth (1y) (2015 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,015.37 Bn | 1,015.37 Bn | - | - |
| 4 | BeOne Medicines | 471.39 Bn | 466.59 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 122.52 Bn | 115.28 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 70.33 Bn | 61.58 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | 158.60% |
| 10 | Regenxbio | 507.22 Mn | 277.15 Mn | 21.22 Mn | -65.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -65.35% |
| Sep 30, 2025 | -38.01% |
| Jun 30, 2025 | -8.45% |
| Mar 31, 2025 | 160.64% |
| Dec 31, 2024 | 22.41% |
| Sep 30, 2024 | 17.93% |
| Jun 30, 2024 | 3.86% |
| Mar 31, 2024 | 31.47% |
| Dec 31, 2023 | -3.53% |
| Sep 30, 2023 | 2.08% |
| Jun 30, 2023 | 23.36% |
| Mar 31, 2023 | -44.73% |
| Dec 31, 2022 | -111.53% |
| Sep 30, 2022 | -18.71% |
| Jun 30, 2022 | -71.18% |
| Mar 31, 2022 | -26.93% |
| Dec 31, 2021 | 765.25% |
| Sep 30, 2021 | -16.57% |
| Jun 30, 2021 | -67.81% |
| Mar 31, 2021 | -23.82% |